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Background 
Lower respiratory tract infections are often treated with 
antibiotics without evidence of clinically relevant bacterial 
disease. Serum calcitonin precursor concentrations, 
including procalcitonin, are raised in bacterial infections, but 
not in viral infections. 
Hypothesis 
Procalcitonin (PCT)-guided treatment of suspected lower 
respiratory tract infection substantially reduces antibiotic use 
without compromising clinical or laboratory outcomes. 
Methods 
Design: Prospective, cluster-randomized, controlled, single-
blinded intervention trial. 
Setting: Medical emergency department of a 784-bed 
academic tertiary care hospital in Basel, Switzerland. 
Subjects: 243 patients presenting to the emergency 
department who were admitted with suspected lower 
respiratory tract infection as the main diagnosis. 
Intervention: Patients were randomly assigned to either 
standard care (n=199) or PCT-guided treatment (n=124). In 
the latter group, serum PCT concentrations were used to 
advise clinicians. Use of antibiotics was: strongly 
discouraged (PCT <0.1 µg/L), discouraged (≥0.1 and <0.25 
µg/L), advised (≥0.25 and <0.5 µg/L), or strongly advised 
(≥0.5 µg/L). Re-evaluation was possible after 6-24 hours in 
both groups. 
Outcomes: The primary endpoint was antibiotic use with 
analysis by intent to treat. Secondary endpoints included 
clinical and laboratory outcomes. 
Results 
Final diagnoses were pneumonia (36%), acute exacerbation 
of chronic obstructive pulmonary disease (25%), acute 
bronchitis (24%), asthma (5%), and other respiratory 
affections (10%). Serological evidence of viral infection was 
recorded in 141 of 175 tested patients (81%). Bacterial 
cultures were positive from sputum in 51 (21%) and from 
blood in 16 (7%). In the procalcitonin group, the adjusted 
relative risk of antibiotic exposure was 0.49 (95% CI 0.44-
0.55; p<0.0001) compared with the standard group. 
Antibiotic use was significantly reduced in all diagnostic 
subgroups. Clinical and laboratory outcomes were similar in 
both groups. 
Conclusion 
PCT-guided therapy of suspected lower respiratory tract 
infection substantially reduced antibiotic use without 
compromising clinical or laboratory outcomes. 
 
Commentary 
As many as 75% of all antibiotic doses are prescribed for 
acute respiratory tract infections; of these, most are caused 
by viruses not bacteria.
2 Since antimicrobial resistance 
among bacteria is an important public health problem and 
indiscriminate use of antibiotics has been implicated as a 
predisposing factor, it would be useful to have a rapid and Critical Care   April 2005 Vol 9 No 3    Al-Nakeeb and Clermont 
sensitive method for determining the presence of bacterial 
infection to facilitate more judicious use of antibiotics. 
Serum concentrations of PCT are elevated in bacterial 
infections, but not in viral infections. PCT levels have been 
used to determine the presence of bacterial infection in the 
setting of acute respiratory distress syndrome
3 and 
sepsis,
4,5 to reduce unnecessary antibiotic use in 
meningitis,
6 and to predict outcome in critically ill patients 
with ventilator-associated pneumonia.
7 The authors of the 
current study used a new, rapid, and highly sensitive PCT 
assay to assess the likelihood of bacterial infection and 
influence antibiotic use in patients presenting to the 
emergency department with suspected lower respiratory 
tract infection. The use of PCT to guide antibiotic use 
resulted in significantly fewer patients receiving antibiotics 
(44% vs. 83%, p<0.0001) and reduced antibiotic-related 
costs. 
This was a very well done study. However, a few limitations 
should be noted. First, reducing antibiotic therapy can only 
be considered advantageous if withholding antibiotics does 
not worsen clinical outcomes. Although serious adverse 
outcomes, such as death, occurred with similar frequency in 
both study arms, meaningful differences could have been 
missed due to the relatively small sample size. Second, it is 
not clear how the authors chose the cut-offs they used to 
advise clinicians. Other cut-offs might have provided even 
better discrimination. Third, the authors did not state if any 
patients received systemic or inhaled steroids prior to initial 
PCT determinations. Steroids inhibit the secretion of 
numerous cytokines and other pro-inflammatory mediators, 
some which are strong inducers of PCT expression and 
secretion.
8,9 Steroid use conceivably could alter PCT levels 
enough to change antibiotic use recommendations. 
Whether the results of this study and the cut-offs used 
would be applicable to patients receiving steroids is 
unknown. Finally, circulating PCT concentrations may be 
increased by noninfectious conditions, such as congestive 
heart failure and cardiogenic shock
10 and may even be low 
in some cases of sepsis due to bacterial infection.
11 
Therefore, PCT concentrations should not be used to 
definitively diagnose bacterial infection and should always 
be considered in the context of other clinical findings 
obtained by taking a thorough history and performing a 
careful physical examination. 
Recommendation 
Based on the results of this study, we conclude that PCT 
testing has the potential to reduce unnecessary antibiotic 
use in patients with suspected lower respiratory tract 
infections. Still, we cannot recommend its routine use until 
larger studies convincingly demonstrate equivalent clinical 
outcomes. Whether these results can be extrapolated to 
situations more relevant to intensivists, such as the 
evaluation of critically ill patients with suspected ventilator-
associated pneumonia,
11 remains to be seen. 
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